Lower dose of PfizerLilly painkiller misses main goals in late stage study

Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study

A lower dose of non-opioid painkiller developed by Pfizer Inc and Eli Lilly and Co failed to meet main goals in a late-stage study in patients with moderate-to-severe osteoarthritis of the hip or knee, the companies said on Thursday.

More From BioPortfolio on "Lower dose of Pfizer-Lilly painkiller misses main goals in late stage study"